Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Novo Nordisk Q2 2018 sales disappoint

Sales of some of Novo Nordisk’s key drugs in second-quarter 2018 fell short of expectations and the drugmaker said prices in the key U.S. market would be lower in 2019.

Read More »

Abbott Labs tops Q2 2018 profit estimates

Abbott Laboratories raised its 2018 full-year earnings forecast and reported a quarterly profit that beat analysts’ estimates, powered by higher sales across its businesses.

Read More »

Johnson & Johnson profit beat fueled by strength in pharma business

J&J topped analysts’ estimates for Q2 2018 profit and revenue with strong demand for the cancer drugs Zytiga and Darzalex.

Read More »

FDA says Mylan’s EpiPen is in shortage

U.S. regulators said Mylan NV’s EpiPen products are in shortage, due to manufacturing delays that are creating intermittent supply constraints of the emergency allergy treatment.

Read More »

Novartis CEO feels heat on U.S. generics

Novartis’ first quarterly results under new CEO Vas Narasimhan were marred by a prized psoriasis treatment that disappointed and a sharp slump in sales by the company’s U.S. generics unit.

Read More »

Pharma Sales Drive J&J’s 2018 First Quarter

Johnson & Johnson reported a strong first-quarter 2018 with $20 billion in sales that was fueled by significant growth in the company’s pharmaceuticals business.

Read More »

Pernix Cuts 22 Percent of Workforce in Reorganization

Pernix Therapeutics is undergoing a reorganization that includes the termination of a number of sales representatives.

Read More »

Pfizer Axes 3 Drugs From Pipeline in Q1 2017

In Pfizer’s first-quarter 2017 financial report, total revenue was down 2 percent year over year. The company also reported three discontinued pipeline projects.

Read More »

AbbVie profit beats on Humira demand

AbbVie Inc. reported a larger-than-expected first-quarter 2017 profit, lifted by demand for the company’s flagship drug Humira.

Read More »

AstraZeneca Dumps Two Drugs From Pipeline

As AstraZeneca faces declining revenue in 2017 from the loss of patents and the challenge of generic drugs, the company culled two drugs from its pipeline.

Read More »

Covance Cuts 100+ Employees in Shut Down

Princeton, N.J.-based CRO Covance plans to shutter its lab in Evansville, Ind., in summer 2017. More than 100 staffers are expected to be laid off.

Read More »

Novartis sets sights on return to growth in 2018

Novartis reported better-than-expected first-quarter 2017 profits with CEO Joe Jimenez remaining confident the Swiss drugmaker would return to growth in 2018.

Read More »

Biogen profit beats analysts’ estimates

Biogen Inc.’s first-quarter 2017 profit blew past analysts’ estimates, helped by higher-than-expected sales of its recently launched spinal muscular atrophy drug Spinraza.

Read More »

J&J first-quarter 2017 revenue misses estimates

Johnson & Johnson reported disappointing pharmaceutical and consumer product sales for first-quarter 2017 as revenue missed analyst estimates.

Read More »

Sanofi sees possibility of lower earnings in 2017

Sanofi expected 2017 EPS to be stable or slightly lower after its fourth-quarter 2016 results were affected by an increase in taxes and one-off charges.

Read More »

Merck 2017 forecast eases analyst concerns

Merck & Co. Inc. reported better-than-expected U.S. quarterly sales for its key cancer drug Keytruda and forecast largely in-line 2017 results.

Read More »

Bone Therapeutics Taps New CEO

Shares of Bone Therapeutics dropped slightly after the company announced a change in leadership and ended plans to hold a clinical trial in the United States.

Read More »

Gilead Racks Up Clinical Failures in Q3 Report

Investors were not particularly happy with Gilead’s Q3 2016 report. In addition to sagging sales and revenue, it outlined a laundry list of failed clinical trials.

Read More »

Biogen Quietly Kills Autoimmune Program

While there were definitely positive items in Biogen’s third-quarter 2016 report, the company also threw in what almost seemed like an afterthought – it was no longer developing amiselimod (MT-1303).

Read More »

Abbott’s third-quarter earnings edge past Street

Abbott Laboratories reported a quarterly profit that edged past estimates as strength in its medical devices business more than offset a decline in its nutrition unit.

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

August 2018 Focus: Top 200 Meds, Year After Launch, VR/AR and more!

Subscribe

Ad Right Bottom